SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of therapies for metabolic and endocrine disorders. The company was founded by Brian Lian and Michael A. Dinerman on September 24, 2012 and is headquartered in San Diego, CA.

Viking Therapeutics Inc

A sharp move in VKTX has reignited speculation about a Big Pharma partnership or buyout, with traders also pointing to attention around its VK2735 obesity-drug program. No deal is confirmed; bullish traders cite possible short covering, while skeptics call the move hype and note that key Phase 3 results are still ahead.

NVIDIA Corp. engages in the design and manufacture of computer graphics processors, chipsets, and related multimedia software. It operates through the following segments: Graphics Processing Unit (GPU) and Compute & Networking. The Graphics segment includes GeForce GPUs for gaming and PCs, the GeForce NOW game streaming service and related infrastructure, Quadro and NVIDIA RTX GPUs for enterprise workstation graphics, virtual GPU, or vGPU, software for cloud-based visual and virtual computing, automotive platforms for infotainment systems, and Omniverse Enterprise software for building and operating metaverse and 3D internet applications. The Compute & Networking segment consists of Data Center accelerated computing platforms and end-to-end networking platforms including Quantum for InfiniBand and Spectrum for Ethernet, NVIDIA DRIVE automated-driving platform and automotive development agreements, Jetson robotics and other embedded platforms, NVIDIA AI Enterprise and other software, and DGX Cloud software and services. The company was founded by Jen Hsun Huang, Chris A. Malachowsky, and Curtis R. Priem in April 1993 and is headquartered in Santa Clara, CA.

NVIDIA Corp

Jensen Huangs abrupt departure as CEO has put Nvidias leadership succession and reports of possible China-related security and export-control concerns at the center of the discussion. Traders are divided between buying the dip and speculating Huang could return, and warning that leadership uncertainty and potential China exposure could weigh on the stock.

Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care and Rare Disease segments. The Diabetes and Obesity Care segment includes diabetes, obesity, cardiovascular, and emerging therapy areas. The Rare Disease segment refers to rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1923 is headquartered in Bagsværd, Denmark.

Novo Nordisk - ADR

Novo Nordisk A/S

Novos stronger quarter and raised outlook, driven by demand for oral Wegovy, are fueling hopes of a recovery as the pill expands the obesity franchise beyond injections. Traders remain divided over whether that momentum can offset pricing pressure, diabetes weakness and competition from Eli Lilly.

Newsmax Inc. is a holding company, which engages in television broadcasting and multi-platform content publishing that produces original news and editorial content for consumers through various media outlets, including TV new channels, digital and print publications. It operates through the Broadcasting and Digital Segments. The Broadcasting segment produces and licenses news, business news and lifestyle content for distribution through both MVPDs and free OTT streaming platforms. The Digital segment is composed of Newsmax.com and affiliated websites. The company was founded by Christopher Ruddy in 1998 and is headquartered in Boca Raton, FL.

Newsmax Inc. - Ordinary Shares - Class B

Newsmax Inc

Newsmaxs stronger-than-expected Q3 results and higher FY26 sales guidance are driving attention, with traders cheering the improving profitability and growth outlook. Bulls are also speculating about a short squeeze, while others remain skeptical and warn that the stocks sharp moves may be volatile.

Cisco Systems, Inc. engages in the design, manufacture, and sale of Internet Protocol-based networking products and services related to the communications and information technology industry. The firm operates through the following geographical segments: the Americas, EMEA, and APJC. Its products include the following categories: Secure, Agile Networks, Internet for the Future, Collaboration, End-to-End Security, Optimized Application Experiences, and Other Products. The company was founded by Sandra Lerner and Leonard Bosack in 1984 and is headquartered in San Jose, CA.

Cisco Systems, Inc.

Ciscos earnings beat and raised full-year outlook have been overshadowed by concerns about lower gross margins from its hardware-heavy AI mix, slower product-order growth, and a softer sequential revenue outlook. Traders are split between viewing the selloff as an overreaction to strong results and questioning whether growth and margins can hold up.

Zevra Therapeutics, Inc. is a commercial-stage rare disease company that combines science, data and patient needs to create therapies for diseases with limited or no treatment options. The firm focuses on the treatment of rare neurological and sleep conditions such as certain Urea Cycle Disorders, Niemann Pick Disease Type C and Idiopathic Hypersomnia. The company receives royalties for AZSTARYS from its commercial partner Corium. The company was founded by Christal M. M. Mickle and Travis C. Mickle on October 30, 2006 and is headquartered in Celebration, FL.

Zevra Therapeutics Inc

Zevra shares are under pressure after the European medicines committee reaffirmed its negative opinion on MIPLYFFA (arimoclomol) for Niemann-Pick disease type C, with a final European Commission decision still pending. Traders debate whether the setback was already expected and overplayed, pointing to U.S. sales and cash, while others criticize management and worry about the lost European opportunity.

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

ImmunityBios third-quarter revenue miss and sequential sales slowdown, alongside concerns about cash needs and limited management guidance, have fueled a sharp selloff and calls for clearer communication. Bulls point to Anktivas expanded bladder-cancer label, positive BCG-naive trial results and upcoming investor conferences, while skeptics question whether commercial execution and revenue growth can catch up.

Advanced Micro Devices, Inc. engages in the semiconductor business. Its products include processors, accelerators, graphics, adaptive SoCs, FPGAs, and SOMs, and software, tools, and apps. The firm offers artificial intelligence, industries, workloads, and gaming solutions. The company was founded by W. J. Sanders III on May 1, 1969 and is headquartered in Santa Clara, CA.

Advanced Micro Devices Inc.

Advanced Micro Devices Inc

AMDs sharp drop is being discussed as a reversal after a rapid rally, amid a broader selloff in semiconductors and AI-linked stocks. Traders disagree on whether this is ordinary profit-taking after an overextended run or a deeper repricing of AI-sector valuations and spending; some also question why AMD is falling despite expectations it could benefit from Nvidias turmoil.

Spdr Dow Jones Industrial Average ETF Trust - Spdr Dow Jones Industrial Average ETF Trust

A sharp rotation out of AI and technology stocks has put the Dow in focus, with traders watching whether DIA can hold up better than the tech-heavy indexes. Some see blue-chip Dow stocks as a relative refuge, while others say the selling has broadened across the market, with inflation and rate concerns adding to volatility.

Autonomi (ANT) is a cryptocurrency launched in 2025and operates on the Arbitrum platform. Autonomi has a current supply of 1,200,000,000 with 346,331,579 in circulation. The last known price of Autonomi is 0.0311505 USD and is down -0.06 over the last 24 hours. It is currently trading on 15 active market(s) with $124,825.83 traded over the last 24 hours. More information can be found at https://autonomi.com.

Aragon

Most of the attention reflects ticker confusion: traders are using Aragons $ANT.X while discussing Anthropics planned IPO and its possible effects on AI stocks and market liquidity. Aragon-specific posts instead mention the projects dissolution and completed token-redemption initiative, with some holders asking about conversion or exchange delisting.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 
